Literature DB >> 30891118

Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.

Simone Brogi1,2, Giuseppe Campiani1, Margherita Brindisi1, Stefania Butini1.   

Abstract

The allosteric targeting of ionotropic glutamate receptors (iGluRs) is a valuable approach for treating various central nervous system (CNS) disorders. In this frame, this Innovations provides a summary of the state-of-the art in the development of allosteric modulators for iGluRs and offers an outlook regarding innovative strategies for treating neurological diseases.

Entities:  

Year:  2019        PMID： 30891118      PMCID： PMC6421537          DOI： 10.1021/acsmedchemlett.8b00450

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  61 in total

1.  Molecular mechanism of AMPA receptor noncompetitive antagonism.

Authors:  Victoria Balannik; Frank S Menniti; Ana V Paternain; Juan Lerma; Yael Stern-Bach
Journal:  Neuron       Date:  2005-10-20       Impact factor: 17.173

2.  Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist.

Authors:  J T Lazzaro; A V Paternain; J Lerma; B L Chenard; F E Ewing; J Huang; W M Welch; A H Ganong; F S Menniti
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

3.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

Review 4.  Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Authors:  Charles R Yang; Kjell A Svensson
Journal:  Pharmacol Ther       Date:  2008-08-27       Impact factor: 12.310

5.  Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats.

Authors:  L Belayev; O F Alonso; Y Liu; A S Chappell; W Zhao; M D Ginsberg; R Busto
Journal:  J Neurotrauma       Date:  2001-10       Impact factor: 5.269

Review 6.  LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

Authors:  Michael J O'Neill; Tracey K Murray; Michael P Clay; Terry Lindstrom; Charles R Yang; Eric S Nisenbaum
Journal:  CNS Drug Rev       Date:  2005

7.  Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

8.  The selective AMPA receptor antagonist GYKI 53784 blocks action potential generation and excitotoxicity in the guinea pig cochlea.

Authors:  J Ruel; R P Bobbin; D Vidal; R Pujol; J L Puel
Journal:  Neuropharmacology       Date:  2000-08-23       Impact factor: 5.250

9.  Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.

Authors:  Shigeki Moriguchi; Norifumi Shioda; Hiroshi Maejima; Xilong Zhao; William Marszalec; Jay Z Yeh; Kohji Fukunaga; Toshio Narahashi
Journal:  Mol Pharmacol       Date:  2006-11-09       Impact factor: 4.436

10.  Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717.

Authors:  R E Hampson; R A España; G A Rogers; L J Porrino; S A Deadwyler
Journal:  Psychopharmacology (Berl)       Date:  2008-11-05       Impact factor: 4.530
View more
  3 in total

Review 1.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 2.  Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.

Authors:  Tanja Veselinović; Irene Neuner
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

Review 3.  The role of carbon dioxide in acute brain injury.

Authors:  Ru-Ming Deng; Yong-Chun Liu; Jin-Quan Li; Jian-Guo Xu; Gang Chen
Journal:  Med Gas Res       Date:  2020 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.